Clinical Trial

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is…

10 months ago

NAVER D2SF-Backed PranaQ® Receives FDA 510(k) Clearance for TipTraQ, an AI-Enabled Home Sleep Apnea Test

SEOUL, South Korea, Feb. 20, 2025 /PRNewswire/ -- PranaQ, backed by NAVER D2SF continues to push the boundaries of AI-powered…

10 months ago

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation ‘Agnostic Diagnostics’ for Respiratory Viruses at the Point of Care

International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance…

10 months ago

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage…

10 months ago

Sitero Announces Explosive Growth, Surpassing 100 Customers on its Mentor eCompliance Platform

MIAMI, Feb. 20, 2025 /PRNewswire/ -- Sitero, a leading provider of Clinical Trial and Research Compliance Technology, today announced it…

10 months ago

COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain…

10 months ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity…

10 months ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase…

10 months ago

PolarityBio Receives U.S. FDA Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers (DFU)

The FDA has granted Breakthrough Therapy Designation for SkinTE based on key positive data from the Phase II study in…

10 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its…

10 months ago